Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
Healthcare
$3.84 -1.11%
-$0.04 today
- Market cap
- $698.58M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
52W Low $1.77High $6.94
Volume 3.99M
Average 2.47M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$162.56M
FY 2025 · Annual
Investing Cash Flow
-$108.76M
FY 2025 · Annual
Financing Cash Flow
$151.51M
FY 2025 · Annual
-22.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| Deferred Income Tax | (624K) | (964K) | (279K) | 0 | 0 |
| Stock-Based Compensation | 1.75M | 6.46M | 13.91M | 26.07M | 29.27M |
| Change in Working Capital | 31.18M | (35.4M) | 2.65M | 31.08M | (5.34M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.19M | 2.46M | 9.14M | (5.26M) | 996K |
| Other Working Capital | 29.99M | (37.86M) | (6.49M) | 36.33M | (6.34M) |
| Other Non-Cash Items | 98.42M | 17.68M | 11.79M | 9.75M | 9.27M |
| Operating Cash Flow | (34.08M) | (131.83M) | (165.41M) | (122.87M) | (162.56M) |
| Capital Expenditures | (4.15M) | (16.1M) | (8.72M) | (7.29M) | (4.53M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (81.98M) | (123.34M) | (104.95M) | (129.45M) | (205.41M) |
| Sales of Investments | 13M | 93M | 132.56M | 204.2M | 101.18M |
| Other Investing Activities | (496K) | (665K) | (170K) | 1M | 0 |
| Investing Cash Flow | (73.63M) | (47.1M) | 18.71M | 68.46M | (108.76M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 270.36M | 185.32M | 655K | 170.14M | 139.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.09M) | (3.82M) | 0 | 25.74M | 12M |
| Financing Cash Flow | 269.28M | 181.49M | 655K | 195.88M | 151.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 161.57M | 2.57M | (146.05M) | 141.47M | (119.82M) |
| Free Cash Flow | (38.23M) | (147.92M) | (174.14M) | (130.16M) | (167.1M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$201.1M
+ D&A$5.4M
+ Stock-Based Comp$29.3M
+ Deferred Tax$0
- Working Capital-$5.3M
+ Other Non-Cash$9.3M
= Operating Cash Flow-$162.6M
- Capex-$4.5M
= Free Cash Flow-$167.1M
Analysis
FY2025 free cash flow is -$167.1M. FCF conversion is 83.1% of net income. Operating cash flow was -$162.6M, with capex of -$4.5M. The largest bridge item is Stock-Based Comp at $29.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 |
Does PRME generate free cash flow?
Prime Medicine, Inc. (PRME) generated -$167.09M of free cash flow in fiscal 2025.
How much operating cash flow does PRME produce?
Operating cash flow was -$162.56M, before capital expenditures of $4.53M.
Continue the stock analysis
Jump to another research area for this company.